



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/609,150	06/25/2003	Birgit K. Jaitner	59516-275/PP-18707.002.	1248

27476 7590 04/27/2006

Chiron Corporation  
Intellectual Property - R440  
P.O. Box 8097  
Emeryville, CA 94662-8097

EXAMINER

MCGARRY, SEAN

ART UNIT	PAPER NUMBER
----------	--------------

1635

DATE MAILED: 04/27/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b>		<b>Applicant(s)</b>	
	10/609,150		JAITNER ET AL.	
	<b>Examiner</b>		<b>Art Unit</b>	
	Sean R. McGarry		1635	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) ☒ Responsive to communication(s) filed on 10 February 2006.
- 2a) ☐ This action is **FINAL**.      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) ☒ Claim(s) 1-23 is/are pending in the application.
- 4a) Of the above claim(s) 7, 12-16 and 20-23 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-6, 8-11 and 17-19 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |  |   |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)  | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)   | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)             |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date <u>6/25/3, 3/18/04, 12/27/05</u> | 6) <input type="checkbox"/> Other: _____  |

### DETAILED ACTION

Applicant's election of Group I, claims 1-6, 9-11, and 17-19, in the reply filed on 2/10/06 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)). Claim 8 is a linking claim.

Claims 7, 12-16, and 20-23 are withdrawn without traverse.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 18 and 19 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 18 and 19 recite "a sequence encoding an antisense oligonucleotide at least 10 nucleotides or nucleotide analogues and not longer than 35 nucleotides in length comprising a sequence selected from the group consisting of SEQ ID NOs: 2 and 3". How does a nucleic acid encode nucleotide analogues? If the sequence is nucleotide analogues, can it be more than 35? How does one know what specifically is a nucleotide analogue beings that in the context of the claims it [a nucleotide analogue]

can be encoded? How can the nucleic acid be 10 or 11 or 12 or etc. . . nucleotides in length if it must comprise SEQ ID NO: 2 or 3 which are both 25 nucleotides in length?

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 1-4, 8, 10, and 17 are rejected under 35 U.S.C. 102(e) as being anticipated by McKay et al [US 6,455,307].

McKay et al disclose SEQ ID NO: 93 which is a 20mer antisense oligonucleotide that comprises at least 10 consecutive nucleic acids of the sequence of the instant SEQ ID NO:1. The oligonucleotide of McKay et al corresponds to residues 3435-3452 of SEQ ID NO: 1. The oligonucleotide is disclosed in a composition comprising pharmaceutically acceptable carriers. The disclosure of McKay et al meets all of the structural requirements of the claimed invention.

**Where applicant claims a composition in terms of a function, property or characteristic and the composition of the prior art is the same as that of the claim but the function is not explicitly disclosed by the reference, the examiner may make a rejection under both 35 U.S.C. 102 and 103, expressed as a 102/103 rejection. "There is nothing inconsistent in concurrent rejections for obviousness under 35 U.S.C. 103 and for anticipation under 35 U.S.C. 102." *In re Best*, 562 F.2d 1252, 1255 n.4, 195 USPQ 430, 433 n.4 (CCPA 1977). This same rationale should also apply to product, apparatus, and process claims claimed in terms of**

Art Unit: 1635

**function, property or characteristic. Therefore, a 35 U.S.C. 102/103 rejection is appropriate for these types of claims as well as for composition claims.**

**“[T]he PTO can require an applicant to prove that the prior art products do not necessarily or inherently possess the characteristics of his [or her] claimed product. Whether the rejection is based on inherency’ under 35 U.S.C. 102, on prima facie obviousness’ under 35 U.S.C. 103, jointly or alternatively, the burden of proof is the same...[footnote omitted].” The burden of proof is similar to that required with respect to product-by-process claims. *In re Fitzgerald*, 619 F.2d 67, 70, 205 USPQ 594, 596 (CCPA 1980) (quoting *In re Best*, 562 F.2d 1252, 1255, 195 USPQ 430, 433-34 (CCPA 1977)).**

Claims 1-5, 8, 10, 11, 18, and 19 are rejected under 35 U.S.C. 102(b) as being anticipated by Schweighoffer et al [US 5,656,595].

Schweighoffer et al have disclosed a nucleic sequence [SEQ ID NO: 5, see column 10, for example] that corresponds to the SOS1 sequence of the instant invention [SEQ ID NO:1]. Schweighoffer et al disclose several SOS1 inhibitors including antisense molecules made of or from SEQ ID NO: 5. At column 3 it is disclosed antibodies, for example. It is disclosed at column 4 that antisense oligonucleotides can be made from all of or a part of SEQ ID NO: 5. It is disclosed that such sequences can be expressed from vectors (see column 4, for example). It is also disclosed at columns 3-4 that the inhibitors are for therapeutic purposes. All of SEQ ID NO: 5 is more than 10 nucleotides. SEQ ID NOS: 2 and 3 are comprised within SEQ ID NO: 5, and would inherently be in an antisense molecule that utilizes all of SEQ ID NO: 5, for example. It is noted that the claims are not limited to antisense oligonucleotides that are SEQ ID NO: 2 or 3 but limited only to comprising 2 or 3 and further there is no limit to the oligonucleotide length in the claims that recite SEQ ID NOS 2 and 3.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 6, 9, and 17 are rejected under 35 U.S.C. 103(a) as being unpatentable over Schweighoffer et al.

Schweighoffer et al have disclosed a nucleic sequence [SEQ ID NO: 5, see column 10, for example] that corresponds to the SOS1 sequence of the instant invention [SEQ ID NO:1]. Schweighoffer et al disclose several SOS1 inhibitors including antisense molecules made of or from SEQ ID NO: 5. At column 3 it is disclosed antibodies, for example. It is also disclosed at columns 3-4 that the inhibitors are for therapeutic purposes. It is disclosed at column 4 that antisense oligonucleotides can be made from all of or a part of SEQ ID NO: 5. It is disclosed that such sequences can be expressed from vectors. All of SEQ ID NO: 5 is more than 10 nucleotides. SEQ ID NOS: 2 and 3 are comprised within SEQ ID NO: 5, and would inherently be in an antisense molecule that utilizes all of SEQ ID NO: 5, for example. It is noted that the claims are not limited to antisense oligonucleotides that are SEQ ID NO: 2 or 3 but limited only to comprising 2 or 3 and further there is no limit to the oligonucleotide length in the claims that recite SEQ ID NOS 2 and 3. Schweighoffer et al do not specifically teach ribozyme inhibitors and do not specifically teach using more than one inhibitor

and do not specifically teach antisense oligonucleotides that are 8 to 35 nucleotides in length.

McKay et al have taught in general terms at columns 4-8, for example, the use of and design of antisense oligonucleotides. It has been taught, at column 7, that antisense oligonucleotides can be 8-50 or 12 to 30 nucleobases in length. It is taught at column 7, that ribozymes are antisense molecules and would therefore be obvious equivalents of non-catalytic antisense molecules. At columns 27-28 it is disclosed the use of various inhibitors in combination with an antisense oligonucleotide.


It would have been obvious to combine the teachings above to make the claimed invention. Schweighoffer et al have taught antisense as well as other inhibitors of SOS1. McKay et al have taught size preferences for antisense oligonucleotides and have taught that ribozymes are antisense compounds. McKay et al have also taught to use more than one inhibitor compound in a composition that may be used as an inhibitory composition.

The claimed invention as a whole would therefore have been prima facie obvious to one in the art at the time the invention was made.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sean R. McGarry whose telephone number is (571) 272-0761. The examiner can normally be reached on M-Th (6:00-4:30).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Andrew Wang can be reached on (571) 272-0811. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



Sean R McGarry  
Primary Examiner  
Art Unit 1635